Business

Theragenics Develops Cancer Treatments

Google+ Pinterest LinkedIn Tumblr


Theragenics has provided men with a non-surgical alternative to treat prostate cancer.

This year, 198,000 new cases of prostate cancer will be diagnosed, with 30,000 of those resulting in death. These figures from the American Cancer Society are not to be ignored, but many men view prostate cancer as a public health concern, not a private concern. What they don”t realize is that prostate cancer affects one out of every six men, while African-American men are twice as likely as Caucasian men to have prostate cancer. Theragenics Corporation is about to reverse that trend.

Started in 1981, Theragenics is dedicated to letting men know that there are solutions to prostate cancer. The producers of TheraSeed, an FDA-licensed device for use in solid localized tumors, Theragenics has provided men with a non-surgical alternative to treat prostate cancer. Whereas traditional treatment involves several hours in surgery, longer hospital recovery time, various side effects and six to eight weeks of recovery, TheraSeed is a one-time, minimally invasive, one-hour, out-patient procedure. Clinical data has proven that in many cases, TheraSeed is a viable option to the surgical alternative.

“Prostate cancer does not have to be a life-altering event. It can be treated and treated effectively if caught early,” said Ron Warren, Director of Investor Relations and Corporate Communications at Theragenics. “Our most famous patient was the former mayor of New York, Rudy Giuliani. He marched seven miles in a parade the day after a TheraSeed procedure. He wouldn”t have been able to do that if he had undergone surgery. Last year we treated 15,000 men for prostate cancer and expect to treat as many or more this year.”

Palladium-103, the main ingredient in TheraSeed, has other benefits besides treating prostate cancer. Every year, 200,000 senior citizens will suffer from macular degeneration and become blind if left untreated. Theragenics and Dr. Paul Finger of the New York University School of Medicine are presently working on using Palladium-103 to treat ocular tumors and macular degeneration. The current treatment for macular degeneration involves rotating the eye in the socket, (severing a muscle in the process) and then treating the eye. But with the prototype instrument that Theragenics is developing, the instrument would go around the back of the eye without severing the muscle and deliver Palladium-103. As there are no effective long-term treatments presently available, Theragenics is excited about moving forward in their effort to find a minimally invasive way of treating macular degeneration.

Founded by a physicist from Georgia Tech, Theragenics” current campus is located on 30 acres in Buford and occupies a 130,000-square-foot building. Theragenics recently built a 35,000-square-foot facility in Oak Ridge, Tennessee that houses a piece of equipment from the Department of Energy. Taking its name from its function, the PSP (plasma separation process) machine can be used to find the proper isotopes for cancer cures, separate heavy isotopes or help the research arm of the government look for specific minerals. With the PSP, Theragenics can do in two years what it would take the government eight years to do and be more cost-effective.

If you”re interested in knowing more about prostate cancer and Theragenics” treatment, call their cancer information center at 1-800-458-4372. For more information about Theragenics Corporation and TheraSeed visit their web sites at www.theragenics.com or www.theraseed.com.